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DIFFERENTIAL EFFECTS OF STATINS ON THE PANCREATIC BETA-CELL  
 
JACOB BODDE 
ABSTRACT 
 Statins are widely used in the treatment of atherosclerosis and 
hypercholesterolemia, both of which are comorbidities of obesity. However, the 
effects statins have on insulin homeostasis are relatively unknown and may 
increase one’s risk for type-II diabetes mellitus. INS-1 pancreatic β-cells, were 
cultured in 11 mM glucose with 25, 50, 100, 200 nM statin or without. 
Specifically, this study observed the effects that pitavastatin, simvastatin, 
lovastatin, and pravastatin have on insulin secretion, insulin content, and ROS 
levels. GSIS was measured after statin and non-statin exposed cells were 
incubated in 12 mM glucose KRB. Insulin content was measured after 
trypsinization and subsequent lysing of cells. Both were analyzed via FRET 
based HTRF assay. ROS levels within cells were measured following statin 
exposure during a 2-hour period of 12 mM glucose oxidation after DCF was 
added. Analysis was done using a Tecan™ fluorescent microplate reader. 
Pitavastatin, simvastatin, and lovastatin decrease glucose stimulated insulin 
secretion and insulin content as compared to control. All concentrations of 
pitavastatin reduced insulin secretion proportionally to insulin content, suggesting 
it does so through impairment of insulin synthesis or storage. Simvastatin 
reduced insulin secretion and content in a dose dependent manner, however 
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when secretion was adjusted for % content, data showed that high doses of 
simvastatin reduced insulin content in a greater fashion than insulin secretion, 
suggesting both secretory mechanisms and storage/synthesis were impaired. 
Lovastatin reduced insulin secretion by a greater amount than its reduction of 
insulin content, suggesting that it impaired insulin secretion via secretory 
mechanism impairment. Pravastatin did not have an effect on either insulin 
secretion or insulin content at any concentration. Cells were also tested to 
determine if pitavastatin, simvastatin, or lovastatin induced a change in ROS 
levels within the cell. None of the three statins tested caused a statistically 
significant change in ROS levels at all concentrations. These results suggest that 
pitavastatin, simvastatin, and lovastatin may impair insulin secretion in patients 
with high blood glucose. As such, clinical guidelines for statin therapy use in 
those who are at risk, or suffer from, diabetes may need to be reevaluated. 
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INTRODUCTION 
OBESITY: A CENTRAL CAUSE AND LINK TO TYPE 2 DIABETES; THE 
ROOT OF THE PROBLEM 
 Approximately one third of all adults in the United States are overweight, a 
statistic that is shared globally [Bastien, et al., 2014]. The percentage of obese 
adults however differs, as nearly 10% of all adults and 26% of US adults are 
obese [Bastien, et al., 2014]. Obesity is defined as a body mass index (BMI) 
equal to or greater than 30.0 [Centers for Disease Control and Prevention, 2017]. 
The prevalence rate of obesity among infants, 2-to-19 year old children, and 
even adults has not changed [Ogden, et al., 2014]. The obesity problem is 
considered an epidemic, with a very incomplete understanding of the causes, 
both physiological and social/psychological. Researchers and medical 
professionals have sought to ascertain the risk factors that contribute to obesity 
as well as the outstanding comorbidities that continue to persist.  
Obesity can be caused genetically by a defect in leptin, a hormone 
produced primarily by white-adipose tissue [Zhang, et al., 1994]. Leptin acts on 
the hypothalamus to reduce food intake [Weigle, et al., 1995], and acts 
peripherally (such as on the liver and pancreas) to increase fatty acid oxidation 
and reduce lipid synthesis [Shimabukuro, et al., 1997]. However, typical obesity, 
not caused by a congenital defect, is associated with a high circulating 
concentration of leptin due to a form of resistance to the hormone [Frederich, et 
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al., 1995]. There are many other genetic factors that predispose individuals to 
obesity as well, such as dysfunction within both the leptin-melanocortin pathway 
[Krude et al., 1998] and the ghrelin hormone receptor [Baessler, et al., 2005].  
However, it is estimated that genetic causes only account for 
approximately 5% of the global obesity cases [Bouchard, 2010]. It stands to 
reason that environmental factors influence weight gain more than genetics, as 
proposed and studied by many researchers. High-fat diets can cause weight gain 
and have been known to do so for a while [Lichtenstein, et al., 1998; Teodoro, et 
al., 2014], but high-carbohydrate diets have similarly been found to cause weight 
gain [Crescenzo, et al., 2015]. Additionally, the quality of fat within an individual’s 
diet can affect weight gain, with diets rich in saturated fats being more 
detrimental than unsaturated fats. The latter being found to even diminish the 
negative impact that saturated fats can have on an individual’s weight gain and 
blood lipid profile [Crescenzo, et al. 2015]. More recent studies are illuminating 
beneficial effects of smaller amounts of polyunsaturated fatty acids such as 
omega 3 that are stored in membranes (phospholipids) and in fat (triglycerides). 
In humans, they have not been shown to aid weight loss, however they can 
attenuate future weight gain and counter metabolic changes from obesity 
[Albracht-Schulte, et al., 2018]. 
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COMORBIDITIES OF OBESITY: AN OVERVIEW 
Obesity carries with it a milieu of dangerous medical comorbidities. As 
such, it is pertinent to dive into the identity of a few of these comorbidities and 
how they originate from obesity. An apparent comorbidity of obesity is joint pain 
caused by arthritis, specifically in the knees [Stürmer, et al., 2000]. This seems to 
be an issue that is greatly associated with a person’s BMI during their 20’s and is 
unique to the knee joint [Gelber, et al., 1999]. The cause of osteoarthritis in an 
obese person’s knees appears to be mechanical in nature [Stürmer, et al., 2000]. 
Several types of cancers also seem to be more prevalent in those who are 
obese. Obesity prolonged throughout adulthood increases the risk for kidney, 
colorectal, liver, pancreatic, stomach, breast (post-menopausal), endometrial, 
and other forms of cancer [World Cancer Research Foundation, 2018]. One 
mechanism in which obesity influences the development is through the over 
secretion of leptin [Somasundar, et al., 2003]. Which has been shown to increase 
the growth of prostate, esophagus, and breast cancers [Somasundar, et al., 
2003]. Additionally, leptin has been shown to have detrimental effect on 
colorectal cancer, enhancing cell invasion [Jaffe and Schwartz, 2008]. Obesity 
can also increase one’s risk for cancer through the proinflammatory cytokines 
that adipocytes release [O’Rourke, 2009]. It has been studied that the serum 
levels of such pro-inflammatory cytokines as TNF-α, IL-6, and even C- reactive 
protein are elevated in the obese [O’Rourke, 2009]. The increased pro-
inflammatory molecules are linked to many different cancers [Coussens and 
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Werb, 2002]. This is an area of emerging research interest since other diseases 
are linked to systemic inflammation [Taylor, et al., 2018]. 
The inflammation promoting cytokines that adipose tissue secretes are 
also linked to non-alcoholic fatty liver disease (NAFLD) and type-II diabetes 
mellitus (T2DM) [O’Rourke, 2009]. These systemic inflammatory states are 
further exacerbated by visceral adipose tissue’s proximity to the liver’s portal 
vein, allowing for drainage of inflammation promoting cytokines and abnormally 
high level of fatty acids directly to the Liver [O’Rourke, 2009]. The increased fatty 
acid synthesis within the liver and uptake from the plasma, while in an obese 
state, causes steatosis as their rates dwarf those of fatty acid export and 
oxidation [Fabbrini, et al., 2010]. NAFLD continues to be an important public 
health concern in part to its high prevalence, it’s risk towards developing liver 
failure, as well as its ability to influence other disease states, such as T2DM and 
dyslipidemia [Marchesini, et al., 2003].  
Another prevalent heath problem linked to obesity is insulin resistance, 
which can similarly, and often in conjunction with NAFLD, lead to cardiovascular 
disease as well as T2DM and dyslipidemia [Ormazabel, et al., 2018]. The 
increased adiposity contributes to systemic inflammation which causes insulin 
resistance through release of pro-inflammatory cytokines, ultimately decreasing 
the effectiveness of insulin’s action on both adipocytes and hepatocytes 
[Halberg, et al., 2009]. The pro-inflammatory molecule TNF-α is elevated in 
adipose tissue and acts through p55 to inhibit IRS-1, a key component in the 
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insulin signal transduction pathway [Peraldi, et al., 1996]. Insulin resistance is 
further induced by TNF-α through its effect on PPARγ, a nuclear hormone 
receptor that drives fat storage and lipid synthesis, This occurs by different 
mechanisms [Ye, 2008]. The first being at the transcriptional level, wherein TNF-
α inhibits the expression of C/EBPδ [Zhang, et al., 1996]. C/EBPδ binds directly 
to DNA in order to activate the gene promoter for PPARγ [Kudo,et al., 2004]. 
Thus, TNF-α indirectly reduces PPARγ. The second model of PPARγ inhibition 
comes from TNF-α’s action on HADC3, a nuclear corepressor of PPARγ [Gao, et 
al. 2006]. TNF-α degrades IkBα, a cytoplasmic binding protein for HADC3, 
causing HDAC3 nuclear translocation and further elevation of HDAC3 levels 
within the nucleus, which leads to a lack of PPARγ expression [Gao, et al., 2006]. 
TNF-α is one of the many ways in which obesity perpetuates insulin resistance, 
which goes so far as stimulating Kupffer cell disruption of insulin signaling within 
the liver [Ye, 2013]. 
Hyperinsulinemia, a constant high level of insulin in the plasma, is 
considered to be caused by insulin resistance, but may however reciprocally act 
to induce insulin resistance. Normal insulin secretion requires plasma free fatty 
acids (FFA) [Stein, et al. 1996] Insulin secretion and is normally a part of a 
negative feedback loop. The plasma level of insulin is determined by the rate of 
clearance of insulin as well as the rate of production [Ye, 2007]. Because of the 
abnormally high concentrations of serum free fatty acids in obesity, the rate of 
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insulin production is tipped into a pathological range that promotes 
hyperinsulinemia [Stein, et al. 1996; O’Rourke, 2009; Milburn, et al., 1995].  
Studies also suggest that both pancreatic β-cell function and cell number 
is enhanced in obesity, which is attributed to fatty acid and glucose stimulation 
related to severe weight gain [Corkey, 2011]. Additionally, leptin inhibits insulin 
production in β-cells [Zhao, et al., 1998]. However, leptin resistance associated 
with obesity [Fredrich, et al., 1995] contributes to an over production of insulin. 
Hyperinsulinemia may also occur when there is deficient clearance of insulin, 
normally performed via the insulin receptor and insulin degrading enzymes in 
primarily the kidney and liver [Polidori, et al., 2016]. When both of these 
pathways were disabled in knockout mice, insulin resistance and T2DM occurred 
[Dodson, et al., 2000; Farris, et al., 2003]. It is important to note that a reduction 
in intra-abdominal adiposity reduces resolves the insulin resistance [Katzel, et al., 
1997]. Ultimately, both overproduction of insulin and deficient insulin clearance 
contribute towards obesity’s ability to induce insulin resistance, an important 
facet of dyslipidemia. 
LIPID METABOLISM AND HOMEOSTASIS 
While the links between obesity and the aforementioned disease states 
are clear and noteworthy, obesity is also linked to dyslipidemia. This is perhaps 
more deleterious as both are significant risk factors for atherosclerosis and thus 
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cardiovascular disease (CVD) [Feingold and Grunfeld, 2000]. For this issue, it is 
important to understand key mechanisms of lipid transport and metabolism. 
Normal lipid homeostasis is a complex pathway that involves several 
lipoproteins, which are emulsion particles that encapsulate a large core of neutral 
lipids. Apo B containing lipoproteins are the primary carriers of triglycerides within 
the blood and serve to transport them to the peripheral parts of the body [Bays et 
al., 2013]. These are mainly (1) chylomicrons and chylomicron remnants (Apo 
B48), which house dietary lipids and are constructed in the enterocyte, and (2) 
very-low density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and 
(3) low-density lipoprotein (LDL) (all of which contain Apo B100) [Bays, et al., 
2013].  
Exogenous lipids are absorbed and packaged into chylomicrons, which 
circulate through the blood after exiting the lymph system [Feingold and 
Grunfeld, 2000]. These chylomicrons release packaged TAG via hydrolysis from 
lipoprotein lipase (LPL), and as it does so the chylomicron grows smaller, 
enriches in cholesterol esters, becomes a chylomicron remnant and acquires 
Apo E. Several apolipoproteins on the surface of the chylomicron are transferred 
to HDL and other lipoproteins [Feingold and Grunfeld, 2000]. The liver then 
clears these chylomicron remnants via binding of the hepatic LDL receptor (LDLr) 
to Apo E, and the cholesterol within the remnant is utilized in the future to form 
VLDL [Feingold and Grunfeld, 2000].  
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Cholesterol and endogenous triglycerides are transferred to Apo B100 to 
create the VLDL particle if triglyceride supply is not limited [Tiwari and Siddiqi, 
2012]. VLDL circulates to the peripheral tissues and functions similarly to 
chylomicrons, wherein triglycerides within the particle are hydrolyzed by LPL, 
forcing it to decrease in size, leave a higher concentration of cholesterol esters, 
and become its remnant, IDL (which can also be removed by the liver via the 
ApoE-LDLr interaction) [Dallinga-Thie, et al., 2010]. The new IDL particle’s 
remaining triglycerides are depleted by hepatic lipase and its exchangeable 
apolipoproteins are transferred, causing it to form LDL. LDL primarily consists of 
cholesterol esters and apo B100, with its function to deliver cholesterol to cells 
[Zhang, et al., 2012] 
The liver removes approximately 70% of plasma LDL via the LDL 
receptor, with the remaining 30% attributed to extra-hepatic removal [Feingold 
and Grunfeld, 2000]. Ultimately, the number of LDL receptors is what determines 
the plasma LDL levels, and the expression of the LDL receptor is regulated by 
cellular cholesterol content [Zhang, et al., 2012; Brown, et al., 2018]. As the 
levels of cholesterol within a cell decrease, the sterol regulatory element binding 
proteins (SREBPs) become active, which are transcription factors that induce the 
transcription of the LDL receptor and HMG CoA reductase, the rate limiting 
enzyme in the synthesis of cholesterol [Brown, et al., 2018]. The opposite occurs 
when cholesterol levels are too high within the cell [Brown, et al., 2018].  
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Peripheral cells receive cholesterol from lipoproteins and can synthesize it 
on their own, but do not have the capability of catabolizing cholesterol [Feingold 
and Grunfeld, 2000]. Cholesterol removal involves efflux of cholesterol, via the 
ABCA1 transporter, from hepatic and extrahepatic tissues to the structural 
protein Apo A-I, which is known as a nascent high-density lipoprotein (HDL) 
particle [Rosenson, et al., 2012]. Cholesterol that has effluxed from a cell to HDL 
remains localized as free cholesterol within the surface of the nascent particle. In 
order for the HDL particle to become mature, lecithin:cholesterol acyltransferase 
(LCAT) removes an ester group from a fatty acid within a phospholipid and 
transfers it to the free cholesterol, creating a cholesterol ester [Ossoli, et al., 
2016]. LCAT is an associated enzyme of HDL and is activated by Apo A-I 
[Ossoli, et al., 2016]. As the cholesterol esters increase, a core is created within 
the center of the HDL particle, causing it to grow [Feingold and Grunfeld, 2000]. 
Cholesteryl ester transfer protein (CETP) exchanges the cholesterol within HDL 
for triglycerides from lipoproteins containing Apo B [Mabuchi, et al., 2014]. HDL 
then becomes filled with triglycerides and can be metabolized by hepatic lipases 
[Feingold and Grunfeld, 2000]. The cholesterol carried by the HDL particle is 
primarily taken up by the liver, a process which is mediated by the SR-BI [Trigatti, 
2017]. 
OBESITY AS A LINK TO DYSLIPIDEMIA 
Dyslipidemia itself is defined by a lipid profile of elevated VLDL, LDL, Apo 
B, serum triglycerides, and a decreased level of HDL [Feingold and Grunfeld, 
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2000; Miller, 2009]. There are many aspects that link obesity to dyslipidemia, 
such as adiposity location and metabolic function. 
Elevated VLDL, a key component of dyslipidemia, is caused by the 
increased synthesis of triglycerides from the liver [Donnelly, et al., 2005]. A fatty 
liver in conjunction with a greater visceral and total body adiposity is the source 
of a larger access to FFAs for triglyceride synthesis [O’Rourke, 2009], pushing it 
towards pathological levels [Donnelly, et al., 2005]. A failure to attenuate 
triglyceride lipolysis, due to insulin resistance, also contributes to increased fatty 
acid delivery to the liver, resulting in the elevated VLDL profile [Donnelly, et al., 
2009; Yu and Ginsberg, 2005].  
Additionally, obesity causes a reduction in mRNA expression of lipoprotein 
lipase in adipose tissue. This directly reduces the activity of LPL, and thus the 
lipolysis of triglyceride-rich lipoproteins [Clemente-Postigo, et al., 2011]. This 
leads to an elevation in FFA levels, causing LPL displacement from the 
endothelium to VLDL and IDL, and further TAG depletion from these lipoproteins 
[Peterson, et al., 1990; Klop, et al., 2013]. The increased TAG displacement 
contributes to greater exchange of TAG from these remnants to HDL for 
cholesterol-esters via CETP, resulting in elevated LDL [Capell, et al., 1996; Klop, 
et al., 2013]. In hypertriglyceridemia however, the cholesterol-ester content of 
LDL decreases, and TAG content increases due to CETP activity. Further 
alterations occur via hepatic lipase hydrolysis of the TAG content within the LDL 
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particle, creating small dense LDL, a pro-atherogenic lipoprotein [Tchernof, et al., 
1996; Deighan, et al., 2001]. 
Obesity’s role in reducing levels of HDL in obese persons is particularly 
detrimental as HDL has been known to be atheroprotective [Poti, et al., 2014]. 
Specifically, the subforms of HDL2 and apolipoprotein A-I [von Eckardstein, et al., 
1994]. HDL2 is less dense and contains more cholesterol on a per particle basis 
than HDL3. Apo A-I, the major protein component of HDL, is in high concentration 
within the HDL2 subfraction [Rashid and Genest, 2007]. Apo A-I has been shown 
to prevent the self-aggregation and oxidation of LDL particles within the arterial 
wall [Khoo, et al., 1990].  
A reduction in HDL2 population, which directly lowers apo A-I levels, can 
also indirectly occur in obesity due to obesity’s deleterious effect on metabolism. 
Hypertriglyceridemia, following an increase in hormone sensitive lipase activity 
due to obesity-related insulin resistance, causes an increase VLDL particles 
[Ginsberg, 2000]. Higher VLDL numbers result in an increase in TAG transfer to 
HDL, creating more triglyceride-rich HDL2 particles, the desired substrate for 
hepatic lipase, allowing for greater hepatic uptake of HDL2 [Rashid and Genest, 
2007]. This issue is three-fold, as both HPL and CETP activity are greater in 
obese individuals, with the HPL activity being further increased in insulin resistant 
states [Arai, et al., 1994; Baynes, et al., 1991].   
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ATHEROSCLEROSIS: A MAJOR HEALTH ISSUE 
 As previously mentioned, obesity is a major risk for atherosclerosis, the 
underlying cause of CVD. Dyslipidemia, insulin resistance, and diabetes mellitus 
are also risk factors for atherosclerosis on their own. However, their perpetuation 
caused by obesity, resulting in simultaneous progression of one or more of these 
diseases, greatly increases that risk [Semenkovich, 2006; Herrington, et al., 
2016]. 
 Briefly, atherosclerosis is a disease involving the build-up of plaque within 
the wall of arteries, which causes a narrowing of the vessel overtime [National 
Heart, Lung, and Blood Institute, 2018]. Atherosclerosis is the leading cause of 
death worldwide and can cause peripheral artery disease, ischemic stroke, and 
ischemic heart disease [Murray and Lopez, 2013; Herrington, et al., 2016]. 
Plaques mature within the intimal wall of an artery and may rupture at their 
luminal surface and can block circulation to cause an ischemic event, such as a 
heart attack [Bentzon, et al., 2014].  
 Hypercholesterolemia, specifically pro-atherogenic lipoproteins like LDL, 
are the main cause of atherosclerosis [National Heart, Lung, and Blood Institute, 
2018].  For a plaque to form, apo-b containing lipoproteins migrate into the intima 
of the artery (sub-endothelium) and become trapped [Klop, et al., 2013]. Small 
dense LDL has an increased affinity for the proteoglycans within the arterial wall, 
which leads to elevated lipoprotein retention [Tabas, et al., 2007]. Within the 
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intima, the lipoproteins aggregate and oxidize, with small dense LDL being more 
susceptible to oxidation due to less anti-oxidative content and free cholesterol 
[Bentzon, et al., 2014; Subramanian and Chait, 2012]. The now oxidized lipid 
fractions, which originated from the modified lipoproteins, chronically stimulate 
the immune system, leading to an increase in pro-inflammatory cytokines as well 
as monocyte differentiation and migration [Bentzon, et al., 2014]. The resulting 
macrophages become deposits for the oxidized moieties and develop into foam 
cells. Eventually, these foam cells gather in great enough layers to become 
visible, yellow, fatty streaks, which can develop into an atherosclerotic lesion 
[Bentzon, et al., 2014].  
These lesions mature when non-cellular lipids accumulate and form a lipid 
core underneath the foam cell layers [Stary, et al., 1994]. These lipid cores can 
become necrotic when macrophages invade and apoptose, leaving oxidized lipid 
debris and cellular remnants, causing an irreversible change to the intima and 
resulting in a fiberoatheroma [Betzon, et al., 2014; Tabas, 2010]. The normal 
connective tissue of the intima is replaced by collagen-rich fibrous tissue by the 
smooth muscle cells, which can create a fibrous cap. The extracellular matrix, 
apoptotic cells, and necrotic core act as locations for calcium deposits, which can 
expand throughout the entire necrotic core [Betzon, et al., 2014]. Further, 
plaques can cause arterial remodeling, causing the arterial segment to expand in 
such a way that the lumen area is not compromised until the plaques are too 
large [Glagov, et al., 1987]. A plaque can also rupture, usually at the thinnest 
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point along the fibrous cap, leading to thrombus formation and acute coronary 
syndrome (ACS) [Betzon, et al., 2014].  
 Treatment modalities for atherosclerosis encompass both lifestyle 
changes and statins. Before pharmaceutical intervention, clinical 
recommendation is based around reducing adiposity and returning metabolism to 
normal. This involves heart-healthy lifestyle changes, such as increasing physical 
activity, managing stress, and a balanced diet [National Heart, Lung, and Blood 
Institute, 2018]. However, lifestyle changes can be difficult to implement, and 
may not be effective, as such pharmaceutical intervention is required. The statin 
therapy for treatment and prevention of atherosclerosis is widely used and 
effective [Bergheanu, et al., 2017]. 
STATIN THERAPY OVERVIEW 
 Statins act primarily by targeting hepatocytes and inhibiting their synthesis 
of cholesterol [Stancu and Sima, 2001]. The rate limiting step in cholesterol 
synthesis involves the enzyme HMG-CoA reductase, which converts HMG-CoA 
into mevalonate, a cholesterol precursor. Statins are competitive inhibitors of 
HMG-CoA reductase, binding to HMG-CoA reductase’s active site and forcing a 
conformational change, resulting in a non-functional enzyme [Mangravite, et al., 
2006; Stancu and Sima, 2001]. The reduction of cholesterol within hepatocytes 
also causes an increase in LDL receptor expression, causing a downstream 
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reduction of circulating LDL, IDL, and VLDL lipoproteins [Stancu and Sima, 2001; 
Sehayek, et al., 1994]. 
 Statins have other impacts on atherosclerosis aside from cholesterol and 
atherogenic lipoprotein reduction. Both simvastatin and fluvastatin inhibit 
cholesterol esterification in macrophages, reducing its accumulation [Bernini, et 
al., 1995]. Additionally, simvastatin and lovastatin have been shown to 
upregulate expression, and inhibit LDL-mediated down-regulation, of the 
atheroprotective eNOS in endothelial cells [Laufs, et al., 1998; Simionescu, et al., 
2002]. Statins can also prevent coronary events via plaque rupture and thrombus 
formation. Specifically, simvastatin and fluvastatin have been shown to cause the 
regression of coronary atherosclerosis and reduce the formation of new lesions 
[Ballantyne, et al., 1997].  
 Statins are some of the most prescribed drugs in the US, in part to their 
general effectiveness as well as the prevalence of atherosclerosis and 
hypercholesterolemia. Atorvastatin and simvastatin (Lipitor and Zocor, 
respectively) are the third and fifth most prescribed drugs, respectively [Fuentes, 
et al., 2018]. With such widespread use of statins, there is increasing evidence to 
suggest complications may arise from statin therapy. Adverse muscle effects are 
the most commonly reported complication of statin therapy [Golomb and Evans, 
2008]. These include muscle pain, weakness, and fatigue. However, 
rhabdomyolysis, severe muscle necrosis that can result in renal dysfunction or 
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failure, is a possible adverse effect from statin therapy when combined with a 
fibrate, another lipid lowering medication [Golomb and Evans, 2008].  
Insulin homeostasis can also be affected by statin therapy. Briefly, insulin 
secretion occurs through the pancreatic β-cell, due primarily from the driving 
force of glucose. Glucose enters the cell via the GLUT2 transporter, where it 
increases in concentration and causes a concomitant increase in the ATP/ADP 
ratio after it undergoes glycolysis. ATP then moves to the KATP channel, binds to 
it, and causes it to close. In doing so, the cell membrane depolarizes and an 
influx of Ca2+ rushes into the cell, wherein it causes insulin exocytosis [Fu, et al., 
2013].  
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Figure 1: Insulin Secretion Pathways 
Although glucose is the primary physiological trigger for insulin secretion, there 
are many other components of insulin secretion. Dysfunction of one of these 
components can lead to metabolic imbalance and disease [Image from Fu, et al., 
2013].  
There are several studies that show some statins may adversely affect 
insulin secretion. Notably, both simvastatin and atorvastatin have been 
suggested to inhibit glucose stimulated insulin secretion (GSIS), the latter 
through inhibition of the Ras/Raf pathway [Scattolini, et al., 2016; Sun, et al., 
2016]. However, other statins such as pravastatin have not shown to have a 
deleterious effect on insulin secretion [Urbano, et al., 2017]. The implications for 
adverse effects on insulin secretion due to statin therapy are concerning to both 
clinicians and patients, as type 2 diabetes is closely linked to dyslipidemia and 
hypercholesterolemia [American Heart Association, 2015]. The nature of statins 
as a treatment for cardiovascular issues gives these implications great 
significance, as type 2 diabetes is linked to obesity, atherosclerosis, and 
dyslipidemia. The patient population that is prescribed statins is already at a 
greater risk for type 2 diabetes due to existing risk factors. As such, it is pertinent 
to study a wide array of statins and their effects on the pancreatic β-cell.  
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SPECIFIC AIMS AND OBJECTIVES 
This study looks to elucidate the effects statins have on glucose 
stimulated insulin secretion and β-cell insulin content. Specifically, pitavastatin, 
pravastatin, simvastatin, and lovastatin effects. 
METHODS 
STATIN PREPARATION 
 Pitavastatin and pravastatin were dissolved in DMSO to a concentration of 
10 mM in order to separate statin ions bound by Ca2+. Statins were then further 
diluted in DMSO to 200 uM, aliquoted and then stored in -20oC. 
 Simvastatin and lovastatin structure contain a lactone and must first be 
activated. 4 mg of each statin was dissolved in 100 μl of ethanol. 150 μl of 0.1 N 
NaOH was added to the solution, which was subsequently incubated at 50oC for 
2 hours. The pH was brought to 7.0 using HCl. Statin solution was then dissolved 
in DMSO to 200 uM, aliquoted, and stored at -20 oC. 
INS-1 (832/13) CELLS 
 INS-1 832/13 clonal pancreatic β-cells were split and then plated onto 
either 48- and 96-well tissue treated plates (Corning, Corning, NY) to the 
approximate density of 260,000 and 130,000 cells per well, respectively. Cells 
were cultured in 11 mM glucose RPMI 1640 media with phenol red with addition 
of 1 mM sodium pyruvate, 10 mM HEPES and 50 μM β-mercaptoethanol. 24-48 
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hours after initial plating, original media was exchanged for fresh 11 mM glucose 
RPMI and statins. Statins were diluted to 200 nM and then serially diluted to 100 
nM, 50 nM, and 25 nM within 11 mM glucose media with 0.1% DMSO for 
addition to cells. Plates contain control wells with 0 nM statin and 0.1% DMSO 
and experimental wells containing the previously stated statin concentrations. All 
conditions were cultured in triplicate. Cells were then incubated for 72 hours prior 
to experiment. 
INSULIN SECRETION  
 Insulin secretion was measured from INS-1 cells grown for 5 days to 
approximately 85% confluence in 48- and 96-well plates. Media that cells were 
incubated in were replaced with 2 mM glucose RPMI without FBS. Cells were 
incubated in that for two hours. Cells were then incubated for 30 minutes in 1 mM 
glucose Krebs-Ringer bicarbonate buffer (KRB) at 37oC. The KRB buffer 
contained 119 mM NaCl, 20 mM HEPES, 5 mM NaHCO3, 4.6 mM KCl, 2 mM 
CaCl2, 1 mM MgSO4, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 0.05% BSA, pH 
7.4. Following the preincubations, INS-1 cells were chilled on ice before 1 mM 
glucose KRB and 12 mM glucose KRB solutions were added. Cells were 
incubated for two hours at 37oC, cooled, and then sampled for insulin secretion. 
Insulin was measured by FRET-based HTRF insulin assay (CisBio, Bedford, 
MA). 
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INSULIN CONTENT 
 INS-1 cells were incubated in trypsin for 5 minutes and then removed. 
Cells are counted by hand via hemocytometer. Cells are then centrifuged to a 
pellet and lysed in cold PBS containing 0.1% Triton X-100 and 25 mM NaOH. 
Insulin content is measured by FRET-based HTRF insulin assay (CisBio, 
Bedford, MA). 
REACTIVE OXYGEN SPECIES MEASUREMENT 
 Intracellular reactive oxygen species (ROS) accumulation was 
approximated by fluorescence assay using 2,7-Dichlorofluorescein diacetate 
(H2DCF-DA; Life Technologies) for a probe. H2DCF-DA diffuses into cells, 
wherein it is enzymatically hydrolyzed to H2DCF by an intracellular esterase. 
After which, the H2DCF is oxidized to DCF, an extremely fluorescent compound 
while in the presence of ROS, the intensity of which is directly proportional to the 
amount of intracellular ROS. 
 After INS-1 cells were incubated with statin (50 nM, 100 nM, 200 nM 
concentrations) and without, cells were incubated in basal (1mM glucose) KRB 
buffer, no serum, with 10 uM H2DCF-DA for 30 minutes at 37oC. Cells were then 
washed with basal KRB buffer, no serum, and incubated in the basal KRB buffer 
without serum and H2DCF-DA for 10 minutes at 37oC. After which, cells were 
chilled and 12 mM glucose KRB buffer with serum was added, and cells were 
incubated for 2 hours.  
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 A fluorescence assay was taken at timepoint 0 (before incubation), 60 
minutes of incubation, and 120 minutes of incubation. Fluorescence was 
measured in a microplate fluorometer (Tecan, Switzerland) at 488 nm excitation 
and 525 nm emission. 
STATISTICAL ANALYSIS 
 The data are shown as the mean of independent experiments ±S.E. 
Comparisons between several means were performed by ANOVA one-way 
analysis of variance test. The level of significance was set at p < 0.05 (*).  
RESULTS 
Pitavastatin Does Not Decrease Basal Secretion 
 
Figure 2: Pitavastatin has no effect on basal secretion 
INS-1 cells were cultured in normal 11 mM glucose culture media with or without 
25 nM, 50 nM, 100 nM, or 200 nM pitavastatin for 72 h. Basal secretion was 
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measured after exposure 1 mM glucose KRB buffer. Figure shows basal 
secretion after exposed to 0, 100, or 200 nM statin. Values were obtained by 
correcting for basal control. Values are not significantly variable (p>0.05). n=3 
experiments. 
 Figure 2 shows that pitavastatin does not affect the basal secretion of 
INS-1 cells. At the highest doses, pitavastatin caused INS-1 cells to basally 
secrete nearly identical to the basal condition. This data suggests that 
pitavastatin may not inhibit insulin secretory mechanisms involved in low glucose 
concentrations. For instance, pancreatic β-cells are known to have Ca2+ 
oscillations for insulin signaling even in basal conditions [Lang, et al., 1979]. 
Pitavastatin may not affect Ca2+ signaling within the β-cell, and thus have no 
impact on basal levels of insulin secretion.  
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Pitavastatin Negatively Affects Insulin Content 
 
Figure 3: Pitavastatin reduces stimulated insulin secretion and insulin content. 
INS-1 cells were cultured in normal 11 mM glucose culture media with or without 
25 nM, 50 nM, 100 nM, or 200 nM pitavastatin for 72 h. A, insulin secretion after 
exposure to these conditions. Values* (p <0.05) are the mean secretion data for 
each condition after correcting for basal secretion. B, insulin content measured 
after exposure to these conditions. Values* (p <0.05) are the mean content data 
for each condition. C, mean insulin secretion data as percent of each conditions’ 
respective insulin content. n=3 experiments for A and B. 
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Figure 3A shows that INS-1 cells incubated in 11 mM glucose culture 
media with pitavastatin for 72 hours caused an inhibition in insulin secretion. 
After accounting for basal secretion, the lowest dose caused a decrease of 
insulin secretion by 33% when compared to control. However, there was no 
dose-dependent decrease in secretion within the range of concentrations. 
Between 25 nM and 50 nM there is a small if any difference, which suggests that 
the two lower concentrations have a similar effect on β-cells. This is unlike the 
effect seen when comparing 50 nM to 100 nM, as insulin secretion drops 
markedly between the two. Additionally, the decrease in secretion at 200 nM 
from 100 nM is a smaller difference than that of 50 nM to 100 nM. While not 
conclusive, this may suggest that the inhibitory effects of pitavastatin begin to 
taper off at higher doses. 
Similar to its effect on insulin secretion, pitavastatin elicits a decrease in 
insulin content, within the INS-1 cells, as seen in Figure 3B. The content 
decreases incrementally as the concentration of statin increases, signifying a 
dysfunction in some aspect of insulin storage.  
Figure 3C represents INS-1 insulin secretion when corrected for total 
insulin content within the cells. Analysis of secretion as a percent of content 
analyzes the cell’s ability to both access its insulin stores and secrete insulin 
properly. Pitavastatin shows a relatively equal percentage of secretion for each 
concentration’s content, suggesting that as its concentration increases, GSIS and 
insulin content decrease similarly. As such, pitavastatin may not impair the 
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secretory mechanism involved in insulin secretion, but instead impair insulin 
synthesis and/or storage mechanisms.  
Simvastatin Inhibits Insulin Secretion and Decreases Insulin Content  
 
Figure 4: Simvastatin reduces stimulated insulin secretion and insulin content 
INS-1 cells were cultured with simvastatin in 25, 50, 100, and 200 nM 
concentrations in conditions stated previously. A, insulin secretion after exposure 
to those conditions. Values* (p <0.05) are the mean secretion data for each 
condition after correcting for basal secretion. B, insulin content measured after 
exposure to those conditions. Values* (p <0.05) are the mean content data for 
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each condition. C, mean insulin secretion data as percent of each conditions’ 
respective insulin content. n=3 and 2 experiments for A and B 
 Simvastatin has been suggested to inhibit insulin secretion in previous 
studies [Scattolini, et al., 2016]. Figure 4A demonstrates that in the presence of 
simvastatin at 25 nM, 50 nM, 100 nM, and 200 nM, INS-1 cells have a reduced 
ability to secrete insulin in response to stimulatory media (12 mM glucose). 
Additionally, the decrease seen as concentration increases did not seem to be 
attenuated, suggesting that even higher doses than 200 nM may cause more 
severe inhibition of secretion.  
 Insulin content was also negatively affected by simvastatin, as seen in 
figure 4B. At the lowest concentration (25 nM), simvastatin hardly decreases 
insulin content in comparison to control. However, 50 nM nearly halves cellular 
insulin content, with both 100 nM and 200 nM further establishing a decrease in 
insulin content without tempering the effect.  
 While 25 nM simvastatin seems to maintain secretion at a similar % of 
content to the control, the higher concentrations do not, as seen in figure 4C. 
With a reduction in both secretion and insulin content, an increase in a larger 
percentage of content being secreted may imply that the rate at which secretion 
occurs is similar to the control’s rate. However, since the cell has access to a 
lesser pool of insulin, cell secretion is deceased. It is equally possible that the 
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insulin pool available was disproportionately decreased, such that the decreased 
rate of secretion was still greater than its access to the cell’s insulin stores. 
Lovastatin Negatively Impacts Both Insulin Secretion and Storage
 
Figure 5: Lovastatin reduces stimulated insulin secretion and insulin content. 
INS-1 cells were cultured with lovastatin in 25, 50, 100, and 200 nM 
concentrations in conditions stated previously. A, insulin secretion after exposure 
to those conditions. Values* (p <0.05) are the mean secretion data for each 
condition after correcting for basal secretion. B, insulin content measured after 
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exposure to those conditions. Values* (p <0.05) are the mean content data for 
each condition. C, mean insulin secretion data as percent of each conditions’ 
respective insulin content. n=2 experiments for A and B, 
  Lovastatin caused a significant inhibition in insulin secretion even at the 
lowest dose, as seen in figure 5A. However, the inhibition began to taper 
between 50 nM and 100 nM. At 100 nM and 200 nM concentrations, the effect on 
insulin secretion was almost equivalent. This suggests that the inhibitory effect of 
lovastatin begins at a low dose but quickly reaches its maximum effect.  
 That effect is not mirrored in lovastatin effect on insulin content, which is to 
decrease either insulin synthesis or reduce storage function. Figure 5B shows 
that all concentrations aside from 200 nM achieve similar inhibitory results on 
insulin content. The 200 nM concentration nearly decreased the insulin content to 
a fourth of the control. This suggests that a high dose is required to fully realize 
lovastatin’s insulin content lowering effects. One possibility is that there may be a 
compensatory mechanism to maintain insulin content through the lower doses of 
lovastatin that is out competed in 200 nM concentration. 
 Lovastatin’s opposing dose effects on secretion and insulin content are 
shown in figure 5C. As the dose increased, the percent of content being 
secreted decreased, similar to the trend seen in GSIS data. In contrast, at 200 
nM the % of content that was secreted raised to levels a little higher than the 
control. The data implies that low doses of lovastatin negatively impact the 
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secretory mechanisms of insulin secretion, but at higher doses the negative 
impact on insulin storage/synthesis is greater.  
Pravastatin does not Inhibit Insulin Secretion or Decrease Insulin Content 
 
Figure 6: Pravastatin does not negatively affect insulin secretion or content 
INS-1 cells were cultured with pravastatin in 25, 50, 100, and 200 nM 
concentrations in conditions stated previously. A, insulin secretion after exposure 
to those conditions. Values are the mean secretion data for each condition after 
correcting for basal secretion. B, insulin content measured after exposure to 
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those conditions. Values are the mean content data for each condition. C, mean 
insulin secretion data as percent of each conditions’ respective insulin content. 
Significance of both secretion and insulin content data variance is null (p >0.05). 
n=2 experiments for A and B. 
 Pravastatin did not show a significant decrease in insulin secretion or 
insulin content at any concentration, as shown in figure 6A and 6B. Figure 6C 
data shows 50 nM pravastatin may cause an increase in the percent of content 
secreted, but the insulin content value used to determine that was not found to 
be significantly variant from other data points.  
Pitavastatin and, Lovastatin Show a Non-Significant Decrease in ROS Levels
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Figure 7: Simvastatin, lovastatin, and pitavastatin effect on ROS levels following 
glucose oxidation. 
ROS levels in INS-1 cells during a 2 h glucose oxidation period was measured 
following simvastatin, lovastatin, and pitavastatin exposure at 50, 100, and 200 
nM concentrations in normal medium (11 mM glucose) for 72 h. *p < 0.05. n=1 
experiment for A, B, and C. 
 During glucose oxidation, simvastatin at all concentrations had no 
significant effect on intracellular ROS accumulation, as seen in figure 7A. 
Lovastatin showed a non-significant overall reduction in cellular ROS levels. At 
25 and 50 nM, lovastatin did show a significant reducing effect on ROS levels at 
both the 60-minute and 120-minute time point, shown in figure 7B. Pitavastatin 
also showed at 50 nM to reduce ROS levels at the 60-minute timepoint, as 
shown in 7C. More experiments are necessary to determine the effect these 
statins have on intracellular ROS. Current research shows simvastatin inducing 
reactive oxygen species in skeletal myotubes, but there has not been research 
regarding its effect, or the effects of lovastatin and pitavastatin, on pancreatic β-
cells [Kwak, et al., 2012]. 
 This study sought to elucidate the effects that different statins had on 
insulin secretion and insulin content. While mechanistic studies were performed, 
the relationship between content and secretion created a framework for further 
understanding of β-cell injury from statins and insulin homeostasis. In this study, 
pitavastatin, simvastatin, and lovastatin showed significant inhibition of secretion 
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by possibly different mechanisms. Pitavastatin data suggests that insulin content 
reduction could be the driving force behind a decrease in insulin secretion. In 
contrast, simvastatin has been verified to effect Ca2+ signaling [Yaluri, et al., 
2015], hence its decrease in insulin secretion. Similarly, lovastatin appears to 
negatively impact a component of the insulin secretory machinery, causing its 
inhibition of secretion. Next steps will include monitoring Ca2+ oscillations as well 
as measuring ATP and K+ levels to determine secretory defects. While more 
research will be required to figure out how the insulin content is being reduced, 
there are various speculations as to what is causing the reduction. As previously 
mentioned, insulin biosynthesis could be negatively affected, reducing the rate at 
which insulin content is being created and therefore decreasing the amount of 
insulin within a secretory granule. Another possibility is that statins may cause an 
acute hypersecretion of insulin into culture media which depletes insulin content. 
DISCUSSION 
 This study showed that pitavastatin inhibited glucose stimulated insulin 
secretion through its effect on decreased insulin content. These findings are 
supported by another similar in vitro experiment [Zhao, et al. (2015)]. In which, 
atorvastatin, pravastatin, rosuvastatin, and pitavastatin, all inhibited insulin 
secretion when cells were treated with 100 nM of statin. Additionally, these 
statins were shown to be cytotoxic at 100 nM concentration. However, 
pitavastatin was shown to elicit the highest insulin secretion range of all 4 statins 
when stimulated with both physiologic and diabetogenic glucose levels [Zhao, et 
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al., 2015]. Studies performed in vivo have shown different results that suggest 
pitavastatin does not incur risk for developing type-2 diabetes or insulin 
resistance. Clinically, pitavastatin does not have an effect on insulin secretion at 
either low or high glucose levels, does not affect endogenous glucose 
production, and improves insulin sensitivity in patients who are pre-diabetic or 
currently suffer from type-2 diabetes [Braun, et al., 2018; Wang, et al., 2017; 
Satoh, et al., 2012]. In conjunction with this study and the in vitro study 
performed by Zhao, et al., data may suggest that pitavastatin has a noticeable 
impact on insulin secretion, yet negligible in those who suffer from type-2 
diabetes.  
 In contrast, simvastatin has been well studied and shown to be detrimental 
to those who are pre-diabetic or suffer from type-2 diabetes. Even in the 
presence of positive control compounds, such as tolbutamide and KCl, 
simvastatin was shown to decrease insulin secretion [Yaluri, et al., 2015]. 
Simvastatin inhibits insulin secretion through many pathways, however the most 
detrimental is its impact on intracellular Ca2+, a key component in signaling for 
insulin secretion. In pancreatic β-cells, cytosolic Ca2+ concentrations oscillate in a 
pulsatile manner, stimulating insulin secretion. Simvastatin inhibits L-type Ca2+ 
channels, the principle transport protein for Ca2+ movement in response to L-
arginine, thereby reducing intracellular Ca2+ concentrations and preventing 
insulin secretion [Gilon, et al., 1993; Yada, et al., 1999]. Additionally, simvastatin 
has been shown to inhibit the KATP channel, reducing the cell’s ability to 
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depolarize and allow Ca2+ into the cell to trigger insulin exocytosis [Yaluri, et al., 
2015]. This explains this study’s data showing simvastatin’s ability to decrease 
insulin secretion but does not explain its ability to reduce insulin content. More 
research is required. 
 At the current stage, conclusions surrounding lovastatin are not clear, and 
more research focused on statin inhibition of insulin homeostasis is needed to 
elucidate its risk for type-2 diabetes. In vivo, lovastatin was found not to influence 
insulin secretion in patients who currently suffer from, and are treated for, T2DM 
[Johnson, et al., 1990]. Additionally, it was shown that the pharmacokinetics of 
the type-2 diabetic drug chlorpropamide was not affected by lovastatin treatment. 
This study may prove that chlorpropamide treatment offsets any insulin secretion 
impairment lovastatin will produce, as there is some evidence to suggest 
lovastatin has a negative impact on insulin secretion. In vitro, lovastatin was 
shown to block the signaling of phospholipase C, a key enzyme that increases 
cytosolic Ca2+ concentration through its creation of IP3 and diacylglycerol [Li, et 
al., 1993]. Lovastatin selectively reduced the effect of two phospholipase C 
agonists, bombesin and arginine vasopressin [Li, et al., 1993]. It is apparent that 
lovastatin merits additional research, as its effects on insulin secretion are not 
clear. 
 Pravastatin is also a highly studied statin in terms of its effects on 
pancreatic β-cells. As with this study, many researchers have reported that 
pravastatin elicited no effect on insulin secretion [Yada, et al., 1999; Urbano, et 
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al., 2017; Ishikawa, et al., 2006]. Because of this, pravastatin stands out as an 
effective treatment modality for those who are pre-diabetic or diabetic who suffer 
from hypercholesterolemia, dyslipidemia, and/or atherosclerosis [McTavish and 
Sorkin, 1991].  
 Atorvastatin, the most prescribed statin in the US [Fuentes, et al., 2018], 
was not included in our study but will be in our future research. Many studies 
have elucidated the effects that atorvastatin has on insulin secretion. These 
include downregulation of the phosphorylation of key proteins involved in the Ras 
pathway [Sun, et al., 2016]. The Ras complex pathway is the major regulator for 
cell growth and gene transcription [Sun, et al., 2016]. As an HMG-CoA reductase 
inhibitor, atorvastatin reduces the reduction of mevalonate and therefore 
cholesterol. However, mevalonate is utilized in creating farnasylated proteins, 
which are active in perpetuating the signal transduction in the Ras/Raf pathway. 
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Figure 8: Atorvastatin Causes Dysregulation of Ras/Raf Pathway 
Atorvastatin’s effect on FPP reduction causes a downstream inhibition of the 
Ras/Raf pathway. In doing so, CREB, a transcriptional binding protein, is not able 
to bind to the CRE binding element and induce transcription [Image from Sun, et 
al., 2016] 
Inhibition of this cascade causes a decrease in gene transcription and therefore a 
decrease in insulin synthesis [Sun, et al., 2016]. This mechanism by which 
atorvastatin reduces insulin content may be shared by other statins, which will 
require further studies.  
 Although statins cause an imbalance in insulin homeostasis and therefore 
diabetogenic effects, there have been many other aspects of statins that are a 
benefit to the patient. There is ample evidence to suggest that statins act as anti-
inflammatory molecules. For instance, statin inhibition of isoprenoid accumulation 
can deter vascular inflammation, which assists in preventing atherosclerosis 
[Antonopoulos, et al., 2012]. Additionally, statins have shown modest 
antineoplastic properties, specifically in their prevention of colorectal cancer 
[Bardou, et al., 2010]. Lastly, statins have shown neuroprotective effects. 
Simvastatin has been shown to induce Bcl-2 expression and 4-hydroxy-2E-
nonenal in neurons and protect against neuronal cytotoxicity [Johnson-Anuna, et 
al., 2007; Lim, et al., 2006]. These recently elucidated effects of statins have 
shown their far-reaching benefits that have just begun to be understood. 
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 Ultimately, evidence highlights the danger that statins can pose to overall 
health. This danger is unique and paradoxical, as type 2 diabetic patients are 
more likely to die from cardiovascular disease [Jackowski, et al., 2008]. However, 
the efficacy of statins to treat dyslipidemia, hypercholesterolemia, and 
atherosclerosis will stimulate continued debate about whether treatment 
outweighs the risks of developing type-2 diabetes. Clinical guidelines for statin 
therapy use in those who are at risk, or suffer from, diabetes may need to be 
reevaluated.  
  
  
38
Table 1: Summarization Table  
A table summarizing the discussed statins as well as their effects on insulin 
homeostasis. 
Statin 
Chemical 
Name/Trade 
Name 
Effects on Glucose 
Metabolism  
Safe for 
T2DM 
Currently 
Testing in 
Our 
Projects 
Pitavastatin 
-Livalo™ 
-Livazo™ 
-Showed no mean increase in 
blood glucose in diabetic 
patients [Yamakawa, et al., 
2008] 
-Decreased insulin secretion 
and showed cytotoxicity [Zhao, 
et al., 2015] 
Maybe Yes 
Lovastatin 
-Mevacor™ 
-Altoprev™ 
-No effect on insulin secretion 
in diabetic patients [Johnson, 
et al., 1990] 
-Reduced insulin secretion 
through Ca2+ blockage (via 
Phospholipase C inhibition) [Li, 
et al., 1993] 
Maybe 
 
Yes 
Simvastatin 
-Zocor™ 
-FloLipid™ 
-Inhibits Ca2+ signaling, the 
KATP channel, and blocks L-
type Ca2+ channels in MIN6 
[Yada et al., 1999; McTavish 
and Sorkin, 1991]. 
No Yes 
Pravastatin 
-Pravachol™ 
-Does not affect insulin 
secretion [Yada, et al., 1999; 
Urbano, et al., 2017; Ishikawa, 
et al., 2006] 
Yes Yes 
Atorvastatin 
-Lipitor™ 
-Inhibits insulin synthesis via 
Ras/Raf pathway through its 
reduction of mevalonate [Sun, 
et al., 2016]. 
No No 
 
Our research will continue to analyze statin alterations in insulin 
homeostasis. Next steps will include studying things like intracellular lipids and 
Ca2+ signaling in order to analyze the effects statins have on the β-cell. 
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Table 2: Future steps for our research. 
This table highlights the future research that will be done to the previously 
studied statins in order to gain more insight into their effects on insulin 
homeostasis. 
Future Research Description 
Insulin secretion (kinetic studies) - β-cell perifusion to monitor the 
oscillatory patterns of insulin 
secretion after chronic statin 
exposure. 
Intracellular lipid accumulation - Image analysis of intracellular 
triglyceride accumulation via 
fluorescence microscopy using Nile 
Red. Cholesterol ester kit (abcam) 
will be used to quantify total 
cholesterol and cholesterol esters 
Membrane potential and intracellular 
calcium 
- Using Fura 2 and bis-oxonol, 
cellular mechanisms used in insulin 
signaling will be evaluated.  
ROS - Continue with ROS measurements 
during glucose oxidation as well as 
ROS levels due to statins in culture  
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